The launch makes remote monitoring capabilities available for all of Senseonics Eversense and Eversense XL continuous glucose monitoring (CGM) users on Android and iOS operating systems in the U.S. and Europe, respectively.
Senseonics developed the Eversense NOW remote monitoring app to allow for real-time glucose data and alerts from Eversense CGM sensor users to be remotely shared. Up to five people can remotely receive updated readings approximately every five minutes, and they can easily view recent trends and alerts.
“The value of remote monitoring in healthcare has never been clearer than in the last two years, with tools providing added peace of mind for users and their support system,” Ascensia Diabetes Care’s Head of the Senseonics CGM business unit Elaine Anderson said in a news release. “Managing diabetes requires continuous monitoring and decision making, and this app makes it easier for friends and family to be part of that process. Having a well-informed support network can reduce the burden placed on people with diabetes, and we are excited to bring this useful tool to all Eversense users in Europe.”
The launch of the CGM in Europe follows last month’s news that Senseonics’ Eversense E3 180-day CGM won FDA approval, extending the wear time from 90 days. Ascensia Diabetes Care, Senseonics’ global commercial partner, will execute the launch, as it is doing with the Eversense NOW remote monitoring app in Europe. Eversense E3 already held European approval before receiving the FDA nod.